Breast cancer: An insight into its inflammatory, molecular, pathological and targeted facets with update on investigational drugs

Crit Rev Oncol Hematol. 2020 Oct:154:103070. doi: 10.1016/j.critrevonc.2020.103070. Epub 2020 Aug 29.

Abstract

Cancer is a heterogeneous disease, occurs due to transcriptional changes in genetic and epigenetic including numerous genes and proteins. Worldwide, breast cancer (BC) is the life-threatening malignancies in women, is characterized by the occurrence of more than one molecular alteration. The incidence and mortality of BC are growing every day because of the adoption of western living standards, metropolitanization, and more life expectancy. Even though many modern approaches are available for the detection and treatment of BC, despite of these, it remains the topmost cause of death in women. This review highlights various approaches, including the importance of clinical, pathological, and molecular aspects of BC. Moreover, risk factors, biomarkers, immunotherapy, investigational drugs, and their role through tumor targets and immune systems have been discussed for management of BC. Furthermore, various targeting approaches for tumors through nanocarriers and their clinical trials have been elaborated in BC challenges and future perspectives.

Keywords: Breast cancer; Inflammatory breast cancer; Investigational drugs; Metastasis; Molecular facets; Risk factors; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Drugs, Investigational
  • Female
  • Humans
  • Immunotherapy

Substances

  • Drugs, Investigational